Renal failure associated with tyrosine kinase inhibitors-Case report and review of the literature

Anat Gafter-Gvili, Ron Ram, Uzi Gafter, Ofer Shpilberg, Pia Raanani

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Imatinib mesylate (IM), nilotinib and dasatinib are tyrosine kinase inhibitors (TKIs) that have revolutionized the treatment of chronic myeloid leukemia (CML). Data regarding the effect of TKIs on the kidney or their safety in patients with renal failure is lacking. We describe a patient with CML who developed renal failure during IM treatment which resolved upon discontinuation of the drug and was not exacerbated by the administration of nilotinib. The literature reporting on the association between TKIs and renal failure is reviewed and the postulated mechanisms including tubular dysfunction caused by the drug or tumor lysis syndrome are discussed.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalLeukemia Research
Volume34
Issue number1
DOIs
StatePublished - 1 Jan 2010
Externally publishedYes

Keywords

  • CML
  • Imatinib mesylate
  • Renal failure
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Renal failure associated with tyrosine kinase inhibitors-Case report and review of the literature'. Together they form a unique fingerprint.

Cite this